Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rec-3565
- Development stage
- Phase 1
- Lead developer
- Recursion Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
REC-3565 is a selective small molecule inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), developed for the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL) and B-cell lymphomas. It is designed to reduce the risk of hyperbilirubinemia by minimizing off-target inhibition of UGT1A1, which is associated with liver toxicity in other MALT1 inhibitors. The drug was developed using Recursion’s AI-driven multi-parameter optimization platform and has shown durable tumor regressions in preclinical studies both as monotherapy and in combination with BTK inhibitors. The Phase 1 EXCELERIZE clinical trial is currently evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in relapsed or refractory B-cell lymphomas[4][7][9].
- Other names
- REC 3565REC3565REC-3565
02
Targets
MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1)
Beyond the preview
Go deeper on rec-3565.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rec-3565.